Breaking the Spell of ADD/ADHD
Part I asked whether the diagnosis tells us the whole story. Part II asks another question: What happens to the child once we believe it does?
In school offices, pediatric clinics, and family kitchens, a diagnosis can begin changing the story of a child. Restless becomes symptomatic. Dreamy becomes inattentive. Intense becomes impulsive. And once the diagnosis is accepted, another decision often follows: medication.
The Cost of Compliance
The most commonly prescribed ADHD medications include methylphenidate and amphetamine stimulants. They are powerful psychoactive drugs and they carry real risks and adverse effects, including appetite suppression, sleep disturbance, irritability, increased heart rate and blood pressure. Prescription stimulants also carry warnings concerning misuse, abuse, addiction, and overdose. These are not insignificant considerations when the person taking the drug is a developing child—sometimes every day, year after year.
And that raises a larger question: What do we actually know about the whole child over time?
Short-Term Change, Long-Term Questions
The landmark Multimodal Treatment Study of Children with ADHD (MTA) offers an important window.
At the end of its initial 14-month randomized treatment period, carefully managed medication and combined treatment produced greater improvement on several ADHD symptom measures than behavioral treatment or usual community care. But follow the children longer. By three years, the original treatment groups no longer showed significant differences on major ADHD symptom and functioning measures. At six to eight years, the treatment children had originally been assigned did not predict their later functioning.
More recent systematic reviews reveal another striking problem: despite hundreds of ADHD treatment studies, relatively few have followed children long enough to tell us confidently what happens over many years.
So we need to distinguish two very different questions: Can a stimulant change observable symptoms? and Does changing those symptoms change the long-term trajectory of the child's life?
They are not the same question. Short-term symptom control is not necessarily long-term healing.
Are We Treating the Child—or the Environment?
Medication can also become woven into the school day itself. Teachers observe behavior. School expectations influence concerns. Nurses may administer medication. This deserves reflection. Is the goal always the child's well-being? Or can the needs of an overwhelmed classroom, exhausted adults, rigid schedules, and standardized expectations become entangled with what is called treatment?
Why must the child always be made to fit? What if we changed something around the child instead?
Research supports classroom accommodations, parent-focused interventions, behavioral approaches, attention to sleep, physical activity, and individualized educational strategies. Some children may benefit from nutritional investigation or other approaches depending upon their individual circumstances.
A child may need movement breaks. A quieter room. More sleep. Different food. Less screen stimulation. More time outdoors. Smaller learning blocks. Predictable rhythms. Creative work. A parent who understands what overwhelms them. A teacher willing to discover what makes them come alive. The child does not exist in isolation.
Change the environment, the relationships, or the rhythm surrounding a child, and sometimes the child changes too.
Reclaiming the Child
Perhaps the deepest danger of any diagnosis is that eventually we stop seeing the person beneath it. The child begins saying: My ADHD. My disorder. My brain doesn't work right. A description can quietly become an identity.
But no diagnostic category can contain the whole of a child. Not their imagination. Not their sensitivity. Not their humor. Not their grief. Not their brilliance. Not their wildness. Not the way they hear music, love animals, build impossible things, notice what everyone else misses, or come alive when finally given something meaningful enough to hold their attention.
So perhaps reclaiming the child begins with another kind of attention.
Not attention to the behavior we want to eliminate. Attention to the child who has been there all along. Before asking how to make the child easier to manage, let us ask what allows this particular child to thrive. Before assuming medication is the answer, let us investigate the whole ecology of the child's life. Before turning difference into deficiency, let us look for the gift hidden inside the struggle.
And before teaching a child that something is fundamentally wrong with them, perhaps we should become very certain that the problem is actually theirs. It is time to break the spell. To restore curiosity. To restore relationship. To restore the soul of education and the sacredness of difference.
And to reclaim the child from the diagnosis.
References & Further Reading:
Breggin, P. R. (2001). Talking Back to Ritalin: What Doctors Aren't Telling You About Stimulants and ADHD (Rev. ed.). Perseus Books.
Breggin, P. R. (2014). The rights of children and parents in regard to children receiving psychiatric diagnoses and drugs. Children & Society, 28(3), 231–241.
Breggin, P. R. (2000, September 29). Testimony in Behavioral Drugs in Schools: Questions and Concerns. Hearing before the Subcommittee on Oversight and Investigations, Committee on Education and the Workforce, U.S. House of Representatives, 106th Cong., 2nd sess., Serial No. 106-130. Peter Breggin — complete September 29, 2000 congressional testimony
Frances, Allen. (2013). Saving Normal: An Insider's Revolt Against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life. William Morrow.
Gøtzsche, Peter C. (2015). Deadly Psychiatry and Organised Denial. People's Press.
Jensen, Peter S., Hinshaw, S.P., Swanson, J.M. et al (2001). Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and Applications for Primary Care Providers. Pediatrics, 107(4), e68.
Lakhan, S. E., & Kirchgessner, A. (2012). Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: Misuse, cognitive impact, and adverse effects. Brain and Behavior, 2(5), 661–677.
Maté, Gabor. (2001). Scattered Minds: The Origins and Healing of Attention Deficit Disorder. Vintage Canada.
Molina, B. S. G., Hinshaw, S. P., Swanson, J. M., et al. (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child & Adolescent Psychiatry, 48(5), 484–500.
Peterson, B. S., Trampush, J., Maglione, M., et al. (2024). Treatments for ADHD in children and adolescents: A systematic review. Pediatrics, 153(4), e2024065787.
U.S. Food and Drug Administration. (2023, May 11). FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions.
U.S. House of Representatives, Committee on Education and the Workforce, Subcommittee on Oversight and Investigations. (2000, September 29). Behavioral Drugs in Schools: Questions and Concerns. Hearing before the Subcommittee on Oversight and Investigations, 106th Cong., 2nd sess., Serial No. 106-130. U.S. Government Printing Office.
Whitaker, Robert, & Cosgrove, Lisa. (2015). Psychiatry Under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform. Palgrave Macmillan.
Wolraich, M. L., Hagan, J. F., Jr., Allan, C., et al. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528.
Photo Credit: Omer Haktan Bulut-Unsplash